TipRanks
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
UK Market
0HD2
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (0HD2) Share Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

0HD2 Analyst Ratings

Strong Buy
22Ratings
Strong Buy
18 Buy
4 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HD2 Stock 12 Month Forecast

Average Price Target

$366.54
▲(55.36% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $366.54 with a high forecast of $489.00 and a low forecast of $256.00. The average price target represents a 55.36% change from the last price of $235.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"201":"$201","490":"$490","273.25":"$273.3","345.5":"$345.5","417.75":"$417.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":489,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$489.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":366.53684210526313,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$366.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$256.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[201,273.25,345.5,417.75,490],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.52,253.1723076923077,272.8246153846154,292.4769230769231,312.1292307692308,331.78153846153845,351.43384615384616,371.0861538461538,390.73846153846154,410.39076923076925,430.0430769230769,449.69538461538457,469.34769230769234,{"y":489,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.52,243.75206477732794,253.98412955465588,264.2161943319838,274.4482591093117,284.68032388663966,294.9123886639676,305.1444534412955,315.37651821862346,325.6085829959514,335.84064777327933,346.07271255060726,356.3047773279352,{"y":366.53684210526313,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.52,235.2492307692308,236.97846153846154,238.70769230769233,240.43692307692308,242.16615384615386,243.89538461538461,245.6246153846154,247.35384615384615,249.08307692307693,250.81230769230768,252.54153846153847,254.27076923076925,{"y":256,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":466.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.465,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.239,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.125,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.64,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":241.19,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.52,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$489.00Average Price Target$366.54Lowest Price Target$256.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GB:0HD2
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Assigned
10/09/26
Alnylam price target lowered to $336 from $346 at BofAAlnylam price target lowered to $336 from $346 at BofA
Morgan Stanley Analyst forecast on GB:0HD2
Michael Ulz
Morgan Stanley
Morgan Stanley
$300
Hold
27.16%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Solventum Corporation (NYSE: SOLV)
RBC Capital Analyst forecast on GB:0HD2
Luca Issi
RBC Capital
RBC Capital
$350→$345
Buy
46.23%
Upside
Reiterated
10/08/26
Alnylam price target lowered to $345 from $350 at RBC CapitalAlnylam price target lowered to $345 from $350 at RBC Capital
J.P. Morgan Analyst forecast on GB:0HD2
Jessica Fye
J.P. Morgan
J.P. Morgan
$375→$369
Buy
56.40%
Upside
Assigned
09/30/26
Alnylam price target lowered to $369 from $375 at JPMorganAlnylam price target lowered to $369 from $375 at JPMorgan
Cantor Fitzgerald Analyst forecast on GB:0HD2
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$325
Hold
37.75%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), AxoGen (NASDAQ: AXGN) and Biohaven Ltd. (NYSE: BHVN)
Bernstein Analyst forecast on GB:0HD2
Jeffrey Walch
Bernstein
Bernstein
$376
Buy
59.37%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Revvity (NYSE: RVTY)
H.C. Wainwright Analyst forecast on GB:0HD2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$455
Buy
92.85%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Innate Pharma (NASDAQ: IPHA) and Alnylam Pharma (NASDAQ: ALNY)
Truist Financial Analyst forecast on GB:0HD2
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)
Needham Analyst forecast on GB:0HD2
Joseph Stringer
Needham
Needham
$357
Buy
51.32%
Upside
Reiterated
09/17/26
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
BMO Capital Analyst forecast on GB:0HD2
David Lebowitz
BMO Capital
BMO Capital
$318
Buy
34.79%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and Alnylam Pharma (NASDAQ: ALNY)
Jefferies Analyst forecast on GB:0HD2
Faisal Khurshid
Jefferies
Jefferies
$230→$260
Hold
10.20%
Upside
Reiterated
09/08/26
Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies
Barclays Analyst forecast on GB:0HD2
Eliana Merle
Barclays
Barclays
$450
Buy
90.73%
Upside
Reiterated
09/01/26
Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on GB:0HD2
Cory Kasimov
Evercore ISI
Evercore ISI
$325.2
Buy
37.84%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on GB:0HD2
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$318
Buy
34.79%
Upside
Reiterated
08/31/26
Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on GB:0HD2
Edward Tenthoff
Piper Sandler
Piper Sandler
$489
Buy
107.26%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GB:0HD2
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Assigned
10/09/26
Alnylam price target lowered to $336 from $346 at BofAAlnylam price target lowered to $336 from $346 at BofA
Morgan Stanley Analyst forecast on GB:0HD2
Michael Ulz
Morgan Stanley
Morgan Stanley
$300
Hold
27.16%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Solventum Corporation (NYSE: SOLV)
RBC Capital Analyst forecast on GB:0HD2
Luca Issi
RBC Capital
RBC Capital
$350→$345
Buy
46.23%
Upside
Reiterated
10/08/26
Alnylam price target lowered to $345 from $350 at RBC CapitalAlnylam price target lowered to $345 from $350 at RBC Capital
J.P. Morgan Analyst forecast on GB:0HD2
Jessica Fye
J.P. Morgan
J.P. Morgan
$375→$369
Buy
56.40%
Upside
Assigned
09/30/26
Alnylam price target lowered to $369 from $375 at JPMorganAlnylam price target lowered to $369 from $375 at JPMorgan
Cantor Fitzgerald Analyst forecast on GB:0HD2
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$325
Hold
37.75%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), AxoGen (NASDAQ: AXGN) and Biohaven Ltd. (NYSE: BHVN)
Bernstein Analyst forecast on GB:0HD2
Jeffrey Walch
Bernstein
Bernstein
$376
Buy
59.37%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Revvity (NYSE: RVTY)
H.C. Wainwright Analyst forecast on GB:0HD2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$455
Buy
92.85%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Innate Pharma (NASDAQ: IPHA) and Alnylam Pharma (NASDAQ: ALNY)
Truist Financial Analyst forecast on GB:0HD2
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)
Needham Analyst forecast on GB:0HD2
Joseph Stringer
Needham
Needham
$357
Buy
51.32%
Upside
Reiterated
09/17/26
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
BMO Capital Analyst forecast on GB:0HD2
David Lebowitz
BMO Capital
BMO Capital
$318
Buy
34.79%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and Alnylam Pharma (NASDAQ: ALNY)
Jefferies Analyst forecast on GB:0HD2
Faisal Khurshid
Jefferies
Jefferies
$230→$260
Hold
10.20%
Upside
Reiterated
09/08/26
Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies
Barclays Analyst forecast on GB:0HD2
Eliana Merle
Barclays
Barclays
$450
Buy
90.73%
Upside
Reiterated
09/01/26
Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on GB:0HD2
Cory Kasimov
Evercore ISI
Evercore ISI
$325.2
Buy
37.84%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on GB:0HD2
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$318
Buy
34.79%
Upside
Reiterated
08/31/26
Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on GB:0HD2
Edward Tenthoff
Piper Sandler
Piper Sandler
$489
Buy
107.26%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
24/39 ratings generated profit
62%
Average Return
+5.47%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +5.47% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
20/28 ratings generated profit
71%
Average Return
+24.49%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +24.49% per trade.
2 Years
David LebowitzBMO Capital
Success Rate
31/44 ratings generated profit
70%
Average Return
+40.10%
Copying David Lebowitz's trades and holding each position for 2 Years would result in 70.45% of your transactions generating a profit, with an average return of +40.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HD2 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
24
34
35
29
13
Buy
14
19
23
24
16
Hold
6
10
9
9
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
63
67
62
35
In the current month, 0HD2 has received 29 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0HD2 average Analyst price target in the past 3 months is 366.54.
Each month's total comprises the sum of three months' worth of ratings.

0HD2 Financial Forecast

0HD2 Earnings Forecast

Next quarter’s earnings estimate for 0HD2 is $1.75 with a range of $1.04 to $2.97. The previous quarter’s EPS was $1.21. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HD2 is $1.75 with a range of $1.04 to $2.97. The previous quarter’s EPS was $1.21. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Sales Forecast

Next quarter’s sales forecast for 0HD2 is $1.42B with a range of $1.26B to $1.49B. The previous quarter’s sales results were $1.29B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HD2 is $1.42B with a range of $1.26B to $1.49B. The previous quarter’s sales results were $1.29B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Stock Forecast FAQ

What is GB:0HD2’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 366.54.
    What is GB:0HD2’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 55.36% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s share price target?
            The average share price target for Alnylam Pharmaceuticals is 366.54. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $489.00 ,and the lowest forecast is $256.00. The average share price target represents 55.36% Increase from the current price of $235.93.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Alnylam Pharmaceuticals?
                To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.